Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation

Histopathology

Volumn 58, Issue 7, 2011, Pages 1167-1172

  Sahm, Felix ^a   Capper, David ^a,b   Meyer, Jochen ^b   Hartmann, Christian ^a,b   Herpel, Esther ^a,b   Andrulis, Mindaugas ^a   Mechtersheimer, Gunhild ^a   Petersen, Iver ^c   Paulus, Werner ^d   Von Deimling, Andreas ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Carcinoma; Haematopoietic tumors; IDH1; Sarcoma

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANGIOSARCOMA; ARTICLE; ASTROCYTOMA; BREAST CARCINOMA; CARCINOID; CARCINOMA; CHOROID PLEXUS PAPILLOMA; CODON; CONTROLLED STUDY; EPITHELIUM TUMOR; GASTROINTESTINAL CARCINOMA; GENE MUTATION; HEMATOPOIETIC SYSTEM TUMOR; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LYMPHOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEDIASTINUM TUMOR; MUTATIONAL ANALYSIS; NASOPHARYNX CARCINOMA; OLIGODENDROGLIOMA; PLASMACYTOMA; PRIORITY JOURNAL; SARCOMA; SQUAMOUS CELL CARCINOMA; SYNOVIAL SARCOMA; THYROID CARCINOMA;

CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; LYMPHOMA; MALE; MUTATION; NEOPLASMS; SARCOMA;

EID: 79959722200     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03823.x     Document Type: Article

References (24)

1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116; 597-602.
2. Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 2009; 118; 469-474.
3. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009; 361; 1058-1066.
4. Chou WC, Hou HA, Chen CY et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010; 115; 2749-2754.
5. Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 Mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17; 225-234.
6. Gross S, Cairns RA, Minden MD et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 2010; 207; 339-344.
7. Bleeker FE, Lamba S, Leenstra S et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 2009; 30; 7-11.
8. Kang MR, Kim MS, Oh JE et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 2009; 125; 353-355.
9. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321; 1807-1812.
10. Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 2009; 27; 5874-5880.
11. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009; 360; 765-773.
12. Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009; 11; 341-347.
13. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462; 739-744.
14. Rzem R, Veiga-da-Cunha M, Noel G et al. A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc. Natl Acad. Sci. USA 2004; 101; 16849-16854.
15. Moroni I, Bugiani M, D'Incerti L et al. L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition? Neurology 2004; 62; 1882-1884.
16. Topcu M, Jobard F, Halliez S et al. L-2-hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. Hum. Mol. Genet. 2004; 13; 2803-2811.
17. Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324; 261-265.
18. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009; 118; 599-601.
19. Capper D, Weissert S, Balss J et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010; 20; 245-254.
20. Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am. J. Surg. Pathol. 2010; 34; 1199-1204.
21. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 18; 1108-1113.
22. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314; 268-274.
23. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun. 2010; 393; 555-559.
24. Andrulis M, Capper D, Luft T, Hartmann C, Zentgraf H, von Deimling A. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leuk. Res. 2010; 34; 1091-1093.